MBX Biosciences, Inc.
mbxbio.comMBX Biosciences Inc (NASDAQ: MBX) is a clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics. The company generates no product revenue, funding operations through capital markets activity while advancing its pipeline toward regulatory approval. MBX reported a net loss of $87.0 million for the year ended December 31, 2025, compared to a net loss of $61.9 million for the year ended December 31, 2024. Net cash used in operating activities was $80.0 million for the year ended December 31, 2025. The company holds a license from Indiana University Research and Technology Corporation (IURTC), under which it owes tiered low-single-digit royalties on net sales, milestone payments up to an aggregate of $0.4 million, and an annual maintenance fee of up to $0.1 million beginning in the first commercial sale year. P. Kent Hawryluk serves as President and Chief Executive Officer, as of the 10-K filed March 12, 2026.
Products & Services
The company is developing peptide-based therapeutics licensed from IURTC. Specific product names and pipeline stage details are not described in the available filing excerpts.
Revenue Model
MBX Biosciences has no product revenue as of the 10-K filed March 12, 2026. Operations are funded through capital raises. Future revenue, if any, would come from net sales of licensed peptide products subject to low-single-digit royalties owed to IURTC, plus potential sublicensing revenue.
Customers & Markets
No commercial customers or end markets are identified in the available filing excerpts. The company has no approved products as of the 10-K filed March 12, 2026.
Geographic Exposure
No geographic revenue breakdown is provided in the available filing excerpts. The company is subject to U.S. federal and state regulatory requirements.
Source: SEC 10-K, filed 2026-03-12
Financial Snapshot
Loading...
